Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06498635 · ClinicalTrials.gov registry record · Phase 3
Immunotherapy After Surgery for People Who Have No Remaining Cancer Cells After Standard Treatment for Early-Stage Non-Small Cell Lung Cancer, INSIGHT Trial
A Phase 3 study of Lung Non-Small Cell Carcinoma and Stage IIIB Lung Cancer AJCC v8, sponsored by National Cancer Institute (NCI).
- Recruiting
- Registry status
- Phase 3
- Development phase
- 306
- Enrollment target
- 20
- Study locations
NCT06498635 is a Phase 3 study of Lung Non-Small Cell Carcinoma and Stage IIIB Lung Cancer AJCC v8 that is actively recruiting participants, run by National Cancer Institute (NCI). The registered enrollment target is 306 participants, above the 154-participant average among 47 other Lung Non-Small Cell Carcinoma trials with a reported enrollment target (99% higher). The trial reports 20 study locations across 7 states.
The verdict
NCT06498635, a Phase 3 study of Lung Non-Small Cell Carcinoma and Stage IIIB Lung Cancer AJCC v8, is actively recruiting participants, sponsored by National Cancer Institute (NCI).
- RECRUITING
- Registry status
- Phase 3
- Development phase
- 306 participants
- Enrollment target
- 20
- Study locations
Study Summary
This phase III trial compares durvalumab to the usual approach (patient observation) after surgery for the treatment of patients with early-stage non-small cell lung cancer. Immunotherapy with monoclonal antibodies, such as durvalumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. The usual approach for patients who are not in a study is to closely watch a patient's condition after surgery and to have regular visits with their doctor to watch for signs of the cancer coming back. Usually, patients do not receive further treatment unless the cancer returns. This study will help determine whether this different approach with durvalumab is better, the same, or worse than the usual approach of observation. Giving durvalumab may help patients live longer and prevent early-stage non-small cell lung cancer from coming back as compared to the usual approach.
Conditions Studied
Interventions
- PROCEDURE Biospecimen Collection
- PROCEDURE Computed Tomography
- BIOLOGICAL Durvalumab
- OTHER Questionnaire Administration
- OTHER Patient Observation
Study Locations (20)
California
- Tower Cancer Research Foundation - Beverly Hills
- Veterans Affairs Loma Linda Healthcare System - Loma Linda
- Cedars Sinai Medical Center - Los Angeles
- University of California Davis Comprehensive Cancer Center - Sacramento
- Torrance Memorial Physician Network - Cancer Care - Torrance
Connecticut
- Hartford HealthCare - Avon - Avon
- Hartford Hospital - Hartford
- Hartford HealthCare - Manchester - Manchester
- Midstate Medical Center - Meriden
- The Hospital of Central Connecticut - New Britain
Delaware
- Beebe South Coastal Health Campus - Millville
- Helen F Graham Cancer Center - Newark
- Medical Oncology Hematology Consultants PA - Newark
- Beebe Health Campus - Rehoboth Beach
Florida
- Moffitt Cancer Center-International Plaza - Tampa
- Moffitt Cancer Center - McKinley Campus - Tampa
- Moffitt Cancer Center - Tampa
Arkansas
- NEA Baptist Memorial Hospital and Fowler Family Cancer Center - Jonesboro - Jonesboro
Colorado
- Saint Mary's Hospital and Regional Medical Center - Grand Junction
Georgia
- Emory University Hospital Midtown - Atlanta
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 306 participants |
| Start Date | 2025-04-01 |
| Est. Completion | 2039-07-15 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06498635
The ClinicalTrials.gov registry entry for NCT06498635 describes a study currently listed as recruiting, categorized as Phase 3. The registered enrollment target is 306 participants, a figure that helps gauge the scale of data the investigators plan to collect, above the 154-participant average among 47 other Lung Non-Small Cell Carcinoma trials with a reported enrollment target (99% higher). The listed sponsor is National Cancer Institute (NCI), which has 3,257 total studies on file at ClinicalTrials.gov.
The record links to 4 conditions, with Lung Non-Small Cell Carcinoma appearing as the primary indexed condition, and to 5 interventions - of which Biospecimen Collection is the first listed.
NCT06498635 reports 20 study locations spanning 7 distinct geographic areas - top geographies include California, Connecticut, Delaware.
Frequently Asked Questions
What is clinical trial NCT06498635 about?
NCT06498635 is a clinical study titled "Immunotherapy After Surgery for People Who Have No Remaining Cancer Cells After Standard Treatment for Early-Stage Non-Small Cell Lung Cancer, INSIGHT Trial". This phase III trial compares durvalumab to the usual approach (patient observation) after surgery for the treatment of patients with early-stage non-small cell lung cancer. Immunotherapy with monoclonal antibodies, such as durvalumab, may help the body's immune system attack the cancer, and may int...
What is the current status of trial NCT06498635?
This trial is currently recruiting. It is a Phase 3 study. The enrollment target is 306 participants. The study started on 2025-04-01. Estimated completion is 2039-07-15.
What conditions does trial NCT06498635 study?
This clinical trial studies the following conditions: Lung Non-Small Cell Carcinoma, Stage IIIB Lung Cancer AJCC v8, Stage IIIA Lung Cancer AJCC v8, Stage II Lung Cancer AJCC v8.
What interventions are being tested in trial NCT06498635?
The interventions under investigation include: Biospecimen Collection (PROCEDURE), Computed Tomography (PROCEDURE), Durvalumab (BIOLOGICAL), Questionnaire Administration (OTHER), Patient Observation (OTHER).
Who is sponsoring clinical trial NCT06498635?
This trial is sponsored by National Cancer Institute (NCI), which has 3,257 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06498635 being conducted?
This trial has 20 study locations across Arkansas, California, Colorado, Connecticut, Delaware. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Lung Non-Small Cell Carcinoma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Testing the Addition of a Type of Drug Called Immunotherapy to the Usual Chemotherapy Treatment for Non-small Cell Lung Cancer, an ALCHEMIST Treatment Trial (Chemo-IO [ACCIO])
RECRUITING · Phase 3
-
Self-Management Survivorship Care in Stage I-III Non-small Cell Lung Cancer or Colorectal Cancer
ACTIVE NOT RECRUITING · Phase 3
-
Testing the Addition of the Drug Atezolizumab to the Usual Radiation Treatment for Patients With Early Non-small Cell Lung Cancer
ACTIVE NOT RECRUITING · Phase 3
-
Nivolumab and Ipilimumab With or Without Local Consolidation Therapy in Treating Patients With Stage IV Non-Small Cell Lung Cancer
ACTIVE NOT RECRUITING · Phase 3
-
Evaluation of Geriatric Assessment and Management for Older Adults With Non-small Cell Lung Cancer Receiving Chemotherapy Radiation Therapy
RECRUITING · NA
-
Cemiplimab and Fianlimab Before Surgery for the Treatment of Stage IB-IIIB Non-Small Cell Lung Cancer
RECRUITING · Phase 2
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.